Category: News

Archive

Categories

Category Tags

409A valuation AI Medical Service AOT asset valuation Biotech firms Biotechgate Biotechgate Digital Partnering brain activity measuring breast cancer Cells clinical trial database Cold Ablation Robotguided Laser Osteotome cranio-maxillofacial surgery Cyrill Bätscher early digestive track cancer detection Ferring Pharmaceutical filming Fujieda Ayumi Funding future of life sciences Gergely Ivanyi German Biotech German Life Sciences GTAI Health Made in Germany Heartseed Inc. HelloPartnering in-licensing opportunities JPM San Francisco Kiyoshi Hasegawa life science database Lily MedTech Inc. medical image analysis NeU Corporation patrik frei product valuation RESI Rhine-Main-Neckar biotech SARS CoV 2 Shiho Azuma Tomohiro Tada valuation Valuation Experts XB-01 Yone Production Co Ltd

Socials Share

  • Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate

    Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate

    Venture Valuation

    Media release

    Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate

    Zurich / Vilnius, Jan 2021 Venture Valuation/Biotechgate announce a cooperation with Enterprise Lithuania, trade promotion governmental agency.

    As per the agreement of the two parties, the Lithuanian Biotech Database has been set-up, a regional portal integrated with Biotechgate Business Development Database. Access to the portal is free for all users, and its main purpose is to promote Lithuanian life science industry globally.  The database provides a profile of all listed companies to foster international collaborations and provide an overview of the key strength of the Lithuanian Life Science industry.

    Additionally, Venture Valuation will be involved in promoting Life Science Baltics, one of Enterprise Lithuania’s flagship events targeted to a global audience. The event will take place on 22-23 September 2021 and over 1,800 world-class biotechnology, pharmaceutical and medical devices experts are expected to attend from more than 40 different countries. 

    “International investors and global pharma and biotech companies are more and more interested in Baltic countries, and we have been actively looking for partners in the region for a while. Enterprise Lithuania is a perfect match for us because they have a special team working exclusively for the life science industry, and they are very close to the startup community.” – Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate

    “Lithuania’s life sciences companies and research teams are ready to help ambitious businesses to take their next big leap. By partnering with Venture Valuation/Biotechgate we hope to spread the message about growing Lithuania’s life sciences environment combined with excellent rankings for our entrepreneurial environment, as well as our leadership in technology, international scientific achievements, up to date infrastructure, highly qualified professionals and science graduates” – Daina Klepone, Managing Director at Enterprise Lithuania

    Lithuanian Biotech Database: www.lithuanianbiotech.com

    Venture Valuation AG – www.venturevaluation.com

    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Enterprise Lithuania – www.enterpriselithuania.com

    Enterprise Lithuania was established by the Lithuanian Ministry of Economy and Innovation in 2009 to promote entrepreneurship, support business development and export of Lithuanian companies, with a focus on SMEs. The agency provides training, consultancy, market analysis, and business-partner search services, and is a dedicated facilitator of the startup ecosystem. Furthermore, Enterprise Lithuania serves as an entry-point and a communication channel for foreign organizations and institutions who wish to explore business opportunities in the country. 

    Download the press release

    Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

  • Launch of the Life Science Directory for Medicen Paris

    Venture Valuation

    Media Release

    Launch of the Life Science Directory for Medicen Paris

    Zurich / Paris, Oct 2020 – Venture Valuation owned Biotechgate announces the partnership with Medicen Paris Region to create a directory of Life Sciences companies. The online directory makes it easier to find partners in one of the key clusters in Europe.

    Venture Valuation/Biotechgate is proud to announce the launch of the Life Science Directory for Medicen Paris created as a result of the partnership between Venture Valuation/Biotechgate and the Medicen biocluster. The directory is accessible for free on the Medicen Paris Region website and features profiles of life science companies located in the region. Advanced search options and an interactive map help to access relevant information very quickly.

    Medicen Paris Region is the largest life science industry organization in France.  The hub represents nearly 500 Medtech, Biotech, e-Health companies, but also Big Pharma and Academics and aim to position the Paris Region as a European leader in the healthcare industry. The directory gathers Medicen’s members through 6 areas: Biotech Therapeutics and Diagnostics, Biotech/ R&D Services, Pharma, Medical Technology, Digital Health, Supplier, Investors, and Others.

    “Entering a partnership with Medicen Paris Region was an important step for us because it is one of the largest life science clusters in Europe. Online business development has received a boost in the recent month, thus tools like the online directory will help companies to continue their deal making activities. Medicen is also an organization that is exceptionally active in promoting its members, so it has been great working with Medicen Paris Region in creating the directory.” Dr. Patrik Frei, CEO and Founder of Venture Valuation/Biotechgate

    “Medicen’s cross-functional expertise allows us to support companies in biotech, medtech as well as e-health fields. The directory built with Venture Valuation/Biotechgate represents an additional opportunity for our network to connect. This partnership strengthens Medicen’s commitment to health innovation ecosystem networking, advise in setting up projects and boost the visibility of its members to offer them the keys to success, in France and internationally.” Jessica Leygues, CEO of Medicen Paris Region

    The directory is published at:

    medicen.org/en/explore-the-network/ and medicen.org/fr/generique-explorer-l-ecosysteme/

    Venture Valuation AG – www.venturevaluation.com

    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Biotechgate – www.biotechgate.com

    Biotechgate is a business development database that contains over 55,000 high-quality profiles of life science companies which include company descriptions, contact information, product pipeline information, financing rounds, management details, and licencing deals. In 2019 a clinical trial database containing over 500,000 records was added to Biotechgate. The new database is integrated with registries around the world.

    Medicen Paris Region –  medicen.org

    The Medicen cluster creates a network of excellence in innovation within the Paris region and beyond. By bringing together private and public players around innovation challenges and with the ambition of developing the therapeutic solutions of tomorrow, Medicen is a trusted third party, supporting the development and completion of projects.

    In order to promote the growth of the sector, the introduction on the market of innovative healthcare products and the creation of jobs, the cluster acts on three levels:

    • Facilitate and encourage the emergence of innovation projects and support their development.
    • Put the right partners in touch with each other to give projects the best possible chance of success.
    • Direct project leaders towards the best public funding mechanisms and help them to obtain funds.

    Download the press release

    Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

  • Site Selection for Life Sciences Companies in Asia – New Report in Collaboration with KPMG

    Venture Valuation

    Zurich / Singapore, July 2020 – In response to the growing need of life sciences companies for comprehensive and unbiased information on various countries and their ability to host key value drivers, KPMG, in collaboration with Venture Valuation has published its report “Site Selection for Life Sciences Companies in Asia” – the first edition. The report examines key trends and opportunities of the Asian Life Sciences sector across multiple regions, including India, China, Hong Kong SAR, Singapore, and the emerging markets of Southeast Asia, with a spotlight on digitalization, clinical trials, and IPOs in selected countries.

    As the latest part of KPMG’s Site Selection for Life Sciences series, the report offers a comprehensive and unique overview of the various aspects relevant to consider setting up regional headquarters, manufacturing, or R&D facilities or investing in the Life Sciences industry in Asia. Such elements include size and specialization of the Life Sciences clusters, regulatory and IPO environment, macroeconomics, and, naturally, the tax system. This combination of operational aspects and tax considerations gives life science companies a first insight into how their new or redesigned value chain could look like in Asia.

    Due to the heterogeneity of Asian countries in terms of the business practices, regulatory environment and maturity of the industry, the report primarily focuses on the four central scenes of the Asian Life Sciences sector: China, Hong Kong SAR, India, and Singapore; but also covers the emerging markets of Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. The chief contribution of Venture Valuation was to provide insights into Initial Public Offerings of Life Sciences companies headquartered in the four main regions.

    “We are happy to have had an opportunity to contribute to another KPMG report and believe that our proprietary database, Biotechgate, that was used to provide the data is the most comprehensive source of information about the Life Sciences industry. Thanks to partnerships with Asian organizations like TCELS, Seoul BioHub or Taiwan Bio Industry Organization we know about the latest news and developments in the region.”

     Dr. Patrik Frei, CEO of Venture Valuation / Biotechgate, Singapore/Switzerland

    To download the report please click here >> 

    Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

  • Launch of the Life Science Cluster Member Directory

    Venture Valuation

    May 2020. Zurich

    Biotechgate/Venture Valuation and The Life Science Cluster (TLSC) announce that they entered a mutual partnership last month. As per the agreement, Venture Valuation created a member directory that has already been implemented in the TLSC website. It features profiles of all the companies being TLSC members along with a map of the cluster and basic sector statistics.

    The Life Science Cluster was established in 2016 to provide a networking platform and support to life science companies, both based in Norway and internationally. It is open to biotech, pharma, and other healthcare companies as well as those whose activity is based on natural resources like the marine sector, agriculture and forestry.

    TLSC is the second Norwegian partner of Biotechgate/Venture Valuation. The company has already been in an active partnership with the Oslo Cancer Cluster for five years.

    The TLSC member directory is available for free at tlsc.no/member-profiles.

    ‘We have a very good experience in cooperation with Norwegian and Nordic in general, industry associations, and are very happy to have TLSC as a partner. Hopefully, we will contribute to the promotion of the cluster and also enrich our global database with information about the Norwegian industry’
    Dr. Patrik Frei, Venture Valuation CEO

    Venture Valuation AG – www.venturevaluation.com
    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Biotechgate – www.biotechgate.com
    Biotechgate is a business development database that contains over 55,000 high-quality profiles of life science companies which include company descriptions, contact information, product pipeline information, financing rounds, management details, and licencing deals. In 2019 a clinical trial database containing over 500,000 records was added to Biotechgate. The new database is integrated with registries around the world.

    The Life Science Cluster – www.tlsc.no
    The Life Science Cluster is a network for all companies and organizations for which the life sciences are key. This includes health and medicine where Norway’s advanced healthcare system forms a unique basis for the development of new technology. It also encompasses the marine sector, agriculture and forestry, where Norway has world leading industries based on Norway’s vast natural resources and strong research-based technology development.

    Download the press release

    Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?

  • Venture Valuation organizes free digital partnering event

    Venture Valuation

    Zurich, May 8th 2020

    Venture Valuation is organizing a virtual partnering event for biotech, pharmaceutical and medical technology companies from May 18 – 20. With the help of the matchmaking platform HelloPartnering other participants can be contacted and meetings arranged in advance. The basic participation is free of charge.

    Download the press release (English)

    Download the press release (German)

     

    More information and registration:
    Visit Biotechgate Digital Partnering »

  • Biotechgate announces the launch of a clinical trial database

    Venture Valuation

    Zurich, 25th March 2019

    Biotechgate announces the launch of a clinical trial database with more than 460,000 trial records. Clinical trial data is imported from more than 13 registries around the world and continuously updated and catalogued. Thanks to the use of newly developed smart software components, the data is presented in a well-structured and easily searchable format, with links to Biotechgate listed companies whenever possible.

    Download the press release

    Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?

  • Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry

    Venture Valuation

    Zurich/Berlin, January 2019;

    Venture Valuation entered into a partnership with HEALTH MADE IN GERMANY, the export promotion program for the German healthcare industry initiated by the German Federal Ministry for Economic Affairs and Energy. HEALTH MADE IN GERMANY is implemented by Germany Trade & Invest (GTAI), the country’s economic development agency.  It is Venture Valuation’s fourth partner in Germany, after BioDeutschland, BioVallley Deutschland, and Cluster Biotechnology North Rhine-Westphalia (BIO NRW).

    As per the partnership agreement, Venture Valuation created a directory of life science, MedTech and eHealth companies located in Germany. The directory is now integrated into the HEALTH MADE IN GERMANY’s website and is accessible for free at the address: www.exportinitiative-gesundheitswirtschaft.de/EIG/Navigation/EN/Company-Directory/company-directory.html.

    The company directory is part of Biotechgate, a global database developed and owned by Venture Valuation. Biotechgate lists around 52,000 life science companies and other organizations, including 3,500 based in Germany.

    ‘We are thrilled to partner with organizations like HEALTH MADE IN GERMANY and GTAI. Germany is one of the biggest life science markets in Europe, so the partnership significantly expands our network. We hope the database will enhance the global exposure of German companies’.

    Dr. Patrik Frei, Venture Valuation/Biotechgate CEO

    ‘Germany’s healthcare industry enjoys an excellent reputation worldwide. German medical technology, pharmaceuticals, digital healthcare solutions, and medical biotechnology are in demand around the globe. Our new online directory of more than 3,500 of the country’s healthcare companies is giving interested people everywhere one-click access to possible business partners here”.

    Kirsten Herrmann, HEALTH MADE IN GERMANY at Germany Trade and Invest (GTAI)

     

    About the partners:

    HEALTH MADE IN GERMANY – www.health-made-in-germany.com | Germany Trade & Invest (GTAI) – www.gtai.de

    HEALTH MADE IN GERMANY is the export initiative for the German healthcare industry. It supports international companies and organizations that are interested in establishing contact with potential German partners and suppliers. Set up by the German Federal Ministry for Economic Affairs and Energy (BMWi), the initiative bundles expert market intelligence for easy industry access.  The HEALTH MADE IN GERMANY initiative is implemented by Germany Trade & Invest, the economic development agency of the Federal Republic of Germany, on behalf of the BMWi.

    Venture Valuation AG – www.venturevaluation.com 
    Venture Valuation specializes in independent, third-party assessment and valuation of biotechnology, pharma and med-tech companies. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and regulatory.

    Biotechgate – www.biotechgate.com
    The Biotechgate Database is a property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 50,000 company profiles and licensing assets and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database of licensing deals and associated financial information on individual deals as well as an investor database.

     
    Would you like to be notified about new reports and other valuable content published by Venture Valuation?

  • Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec

    Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec

    Venture Valuation

    Zurich / Montréal, November 26, 2018

    As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership to make available online a new Directory of Québec-based Life Sciences and Health Technologies companies. The online directory will make it easier to find business partners in Québec and will inform visitors about the strength of the life science ecosystem.

    This collaboration will also ensure international visibility of Québec companies since the database integrated in the Directory is also integrated within Biotechgate, a global database of life sciences companies and organizations, which includes more than 50,000 company profiles. Thanks to a comprehensive search form, it allows users to seek specific companies filtering by sector, product phase and many other categories. User-friendly Québec Life Sciences and Health Technologies directory includes more than 1000 profiles of companies active in the Healthtech, Biotech, Pharma or Medtech sector, all profiles of which being updated continuously. The platform is one of 30 country-specific life science databases, which in collaboration with regional organizations, are run and maintained by Venture Valuation.

    “We are very pleased to partner with Biotechgate which will allow us to enhance the visibility of our Québec companies for investors and potential partners by giving visitors easy and focused access to the actors of our vast network of Biotech, Pharma and Medtech companies. This exclusive Québec Life Sciences database is a perfect tool to promote our innovative life sciences sector.”
    Frank Béraud, CEO of Montréal InVivo

    “We are excited to have Montréal Invivo as a new partner for Biotechgate and strengthen our network in North America. Québec is a very important life sciences hub and a bridge to Europe.”
    Patrik Frei, CEO of Venture Valuation / Biotechgate

    About Biotechgate – www.biotechgate.com
    The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 50,000 company profiles and licensing assets and providing the user with information on life science companies, licensing products, financing rounds as well as key data on management structures and technology platforms. It also contains a database on licensing deals and associated financial information on individual deals as well as an investors database.

    About Venture Valuation AG – www.venturevaluation.com
    Venture Valuation specializes in independent, third-party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Ireland, UK, Canada, USA and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology, pharmaceutical and high technology industries.

     About Montréal Invivo – www.montreal-invivo.com
    About Montréal InVivo – www.montreal-invivo.com Montréal InVivo is the brand name for the life sciences and health technologies (LSHT) cluster of the Montréal metropolitan area. The cluster comprises almost 600 organizations, including more than 150 research centres, 80 subsidiaries of world-class companies and more than 40,000 people employed in the sector. A wellspring of great ideas, the cluster includes four universities and ranks first in Canada for the number of research centres. Montréal InVivo is a non-profit economic development organization dedicated to the creation of wealth. Its activities are supported by funding from the Ministère de l’Économie, de la Science et de l’Innovation (MESI), the Secrétariat à la région métropolitaine reporting to the Ministère des Affaires municipales et de l’Occupation du territoire, the Communauté métropolitaine de Montréal (CMM), Canada Economic Development (CED) for the region of Québec and private and institutional sectors.

    Contacts:

    Venture Valuation, Switzerland
    Patrik Frei
    +41 (43) 321 86 60
    support@biotechgate.com

    Montréal InVivo
    Sabrina Bernier
    514.987.9387
    sbernier@montreal-invivo.com

     

  • The Launch of the BioAlberta Life Sciences Database

    The Launch of the BioAlberta Life Sciences Database

    Venture Valuation

    Zurich, Edmonton January 2018

    BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province.

    As per the partnership agreement, Venture Valuation provided BioAlberta with their proprietary database of Albertan companies and related life science organizations that is now integrated into the BioAlberta website.

    The database displays profiles of all the companies located in the province, as well as those listed in the global Biotechgate database. Additionally, members of BioAlberta are granted an extended profile.

    Besides company profiles, the industry statistics, such as the number of companies by sector, and a breakdown of the industry as a whole by subsector are displayed. Having a company listed on the database is free of charge, and it is possible to edit the content of the profile. Also, getting access to the database through the BioAlberta website doesn’t require a paid subscription.

    Venture Valuation CEO Dr. Patrik Frei said: ‘We are delighted to acquire another valuable partner in Canada. It will allow extending our knowledge about the industry in the country that has a particularly active life sciences market’.

    BioAlberta President and CEO Mel Wong said: ‘BioAlberta is pleased to be a partner with Venture Evaluation in making Biotechgate available to our members.  Access to an industry database has always been an important tool in the work of industry promotion, development, and advocacy.  We look forward to enhancing our support for the biotechnology industry through access to Biotechgate’.

    About partners:

    BioAlberta (www.bioalberta.com) is the central voice and organizing hub for the life sciences industry in Alberta. It is a private, not-for-profit industry association, representing Alberta’s growing life science sector. BioAlberta activity is focused in four key strategic areas: advocacy, promotion & marketing, industry development, and networking.

    Biotechgate (www.biotechgate.com) is a global business development database containing nearly 50,000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms and more.

    Venture Valuation (www.venturevaluation.com) Venture Valuation VV AG is the owner of the Biotechgate Database. The company specializes in independent, third-party assessment, valuation, and monitoring of emerging high growth companies in industries such as biotechnology, med-tech, and high-tech

  • Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

    Life Sciences BC – New Canadian Partner for Venture Valuation/Biotechgate

    Venture Valuation

    Zurich/Vancouver January 2018

    Biotechgate/Venture Valuation announce entering a partnership with Life Sciences British Columbia, a Canadian non-profit organization. The goal of the partnership is to develop and run a database comprised of the life science companies situated in the province of British Columbia. The database will be integrated into the Life Sciences BC website (lifesciencesbc.ca) and access will be provided free of charge to all website users. The database will list all members and sponsors of the organization

    The British Columbia database will be a part of the global Biotechgate database that currently includes over 49,000 companies predominantly from the Biotech, Pharma, Medtech, and eHealth sectors. Additionally, it lists many relevant service providers, investors, media, and academic institutions, as well as non-profit and government organizations. The data is continuously updated by both the Biotechgate team and the listed companies themselves as all of the listed companies have access to the content of their profiles that allows them to contribute to the project. The database features advanced search options that will also be available in the local integration on the Life Science BC website.

    Dr. Patrik Frei, CEO of Venture Valuation said: ‘We hope to gain a better insight into the vibrant life sciences industry in British Columbia thanks to the cooperation with our new partner’

    Dr. Lesley Esford, President of Life Sciences BC said: ‘We are pleased to partner with Biotechgate and expect that this search service will support the needs of our broader community. When you are a small to medium size business, it can be difficult to connect with the best service providers; I’m certain adding the Biotechgate database, will be of overall benefit to our membership.’

    About us:

    Life Sciences British Columbia (lifesciencesbc.ca) is a non-profit, industry association which supports and represents the life science community of British Columbia through leadership, investment, advocacy, and promotion of our world-class life science community.

    Biotechgate (biotechgate.com) is a global business development database containing nearly 50,000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms and more.

    Venture Valuation (venturevaluation.com) Venture Valuation VV AG is the owner of the Biotechgate Database. The company specializes in independent, third-party assessment, valuation, and monitoring of emerging high growth companies in industries such as biotechnology, med-tech, and high-tech.